Why is Hims & Hers Health stock sliding today?

Hims & Hers Health stock is sliding 3.7% in pre-open trading to reach $22.10, extending losses that began after the telehealth company posted a deeply disappointing Q3 2026 earnings report on Monday evening.

The company swung to a net loss of $0.14 per share, badly missing the analyst consensus for a profit of $0.06, while revenue of $890.4 million — though up 49% year-over-year — came in just shy of the roughly $892.9 million the Street had expected.

Making matters worse, Q4 revenue guidance of $875 million to $895 million fell far short of the approximately $955 million consensus, and the company trimmed its full-year adjusted EBITDA outlook to $257 million–$277 million from a prior range of $275 million–$325 million.

A severe compression in gross margins is at the heart of investor concern. Gross margin fell to 57% from 74% a year earlier, driven by the company’s deliberate pivot toward lower-margin branded GLP-1 weight-loss drugs — including those offered through a recently announced Eli Lilly partnership — and the rapid scaling of international operations, where rest-of-world revenue surged 321% year-over-year but at structurally thinner margins.

Subscriber count also dipped sequentially by roughly 100,000 to approximately 2.8 million, which management attributed to intentionally reduced marketing spend ahead of planned platform expansions.

Compounding the negative tone, insiders have been net sellers to the tune of roughly $19.4 million over the past twelve months versus just $1.2 million in purchases, and six analysts have recently revised their earnings estimates downward.

The broader market is providing little support. The S&P 500 is up just 0.1% and the Nasdaq is slightly negative at -0.2%, meaning there is no macro tailwind to cushion HIMS’s company-specific selloff.

On a positive note, the company separately announced plans to expand into unapproved peptide treatments such as NAD+ and sermorelin following an easing of U.S. regulatory restrictions, and appointed Stanford neuroscientist Andrew Huberman to its board of directors — moves that could support long-term brand credibility but are doing little to offset near-term profitability concerns.

Taken together, the combination of a surprise earnings loss, a meaningful revenue guidance cut, and a gross margin that has eroded sharply as the business model transitions away from compounded drugs toward branded alternatives has created a powerful negative catalyst.

With the stock already sitting well below its 52-week high of $41.28 and the pre-market price of $22.10 approaching key technical support levels, sentiment around HIMS remains fragile as the market awaits clarity on the company’s path back to profitability.